1	5	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Fibrin	_	_	NNP	_	_	_	_	_
2	Handling	_	_	NN	_	_	_	_	_
3	for	_	_	IN	_	_	_	_	_
4	Bioactive	_	_	JJ	_	_	_	_	_
5	Compounds	_	_	NNS	_	_	_	_	_
6	Delivery	_	_	NNP	_	_	_	_	_


1	5.1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Tuning	_	_	VBG	_	_	_	_	_
2	Fibrin	_	_	NN	_	_	_	_	_
3	Intrinsic	_	_	JJ	_	_	_	_	_
4	Characteristics	_	_	NNS	_	_	_	_	_


1	Bioactive	_	_	JJ	_	_	_	_	_
2	compounds	_	_	NNS	_	_	_	_	_
3	including	_	_	VBG	_	_	_	_	_
4	growth	_	_	NN	_	_	_	_	_
5	factors	_	_	NNS	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	cytokines	_	_	NNS	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	drugs	_	_	NNS	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	nucleic	_	_	JJ	_	_	_	_	_
13	acids	_	_	NNS	_	_	_	_	_
14	can	_	_	MD	_	_	_	_	_
15	be	_	_	VB	_	_	_	_	_
16	easily	_	_	RB	_	_	_	_	_
17	entrapped	_	_	VBN	_	_	_	_	_
18	in	_	_	IN	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	fibrin	_	_	NN	_	_	_	_	_
21	matrix	_	_	NN	_	_	_	_	_
22	by	_	_	IN	_	_	_	_	_
23	mixing	_	_	VBG	_	_	_	_	_
24	them	_	_	PRP	_	_	_	_	_
25	with	_	_	IN	_	_	_	_	_
26	fibrinogen	_	_	NN	_	_	_	_	_
27	or	_	_	CC	_	_	_	_	_
28	thrombin	_	_	NN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	general	_	_	JJ	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	fibrin	_	_	NN	_	_	_	_	_
5	matrix	_	_	NN	_	_	_	_	_
6	remains	_	_	VBZ	_	_	_	_	_
7	porous	_	_	JJ	_	_	_	_	_
8	regardless	_	_	RB	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	conditions	_	_	NNS	_	_	_	_	_
11	and/or	_	_	JJ	_	_	_	_	_
12	thrombin	_	_	NN	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	fibrinogen	_	_	NN	_	_	_	_	_
15	ratios	_	_	NNS	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	increasing	_	_	VBG	_	_	_	_	_
4	fibrinogen	_	_	NN	_	_	_	_	_
5	and/or	_	_	JJ	_	_	_	_	_
6	thrombin	_	_	NN	_	_	_	_	_
7	concentrations	_	_	NNS	_	_	_	_	_
8	densifies	_	_	VBZ	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	structure	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	a	_	_	DT	_	_	_	_	_
13	fibrin	_	_	NN	_	_	_	_	_
14	gel	_	_	NN	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	reduces	_	_	VBZ	_	_	_	_	_
17	its	_	_	PRP$	_	_	_	_	_
18	degradation	_	_	NN	_	_	_	_	_
19	rate	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	thus	_	_	RB	_	_	_	_	_
22	slowing	_	_	VBG	_	_	_	_	_
23	down	_	_	RP	_	_	_	_	_
24	the	_	_	DT	_	_	_	_	_
25	diffusion	_	_	NN	_	_	_	_	_
26	of	_	_	IN	_	_	_	_	_
27	loaded	_	_	VBN	_	_	_	_	_
28	molecules	_	_	NNS	_	_	_	_	_
29	(	_	_	-LRB-	_	_	_	_	_
30	e.	_	_	FW	_	_	_	_	_
31	g.	_	_	NN	_	_	_	_	_
32	,	_	_	,	_	_	_	_	_
33	FGF	_	_	NNP	_	_	_	_	_
34	)	_	_	-RRB-	_	_	_	_	_
35	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	release	_	_	NN	_	_	_	_	_
6	profile	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	active	_	_	JJ	_	_	_	_	_
9	compounds	_	_	NNS	_	_	_	_	_
10	is	_	_	VBZ	_	_	_	_	_
11	affected	_	_	VBN	_	_	_	_	_
12	by	_	_	IN	_	_	_	_	_
13	their	_	_	PRP$	_	_	_	_	_
14	physicochemical	_	_	JJ	_	_	_	_	_
15	properties	_	_	NNS	_	_	_	_	_
16	including	_	_	VBG	_	_	_	_	_
17	partition	_	_	NN	_	_	_	_	_
18	coefficient	_	_	NN	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	size	_	_	NN	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	functional	_	_	JJ	_	_	_	_	_
23	groups	_	_	NNS	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	For	_	_	IN	_	_	_	_	_
2	example	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	hydrophilic	_	_	JJ	_	_	_	_	_
5	molecules	_	_	NNS	_	_	_	_	_
6	readily	_	_	RB	_	_	_	_	_
7	leach	_	_	VBP	_	_	_	_	_
8	out	_	_	RP	_	_	_	_	_
9	(	_	_	-LRB-	_	_	_	_	_
10	e.	_	_	FW	_	_	_	_	_
11	g.	_	_	FW	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	erythromycin	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	mitomycin	_	_	NN	_	_	_	_	_
16	C	_	_	NNP	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	fluorouracil	_	_	NN	_	_	_	_	_
19	etc.	_	_	FW	_	_	_	_	_
20	)	_	_	-RRB-	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	while	_	_	IN	_	_	_	_	_
23	hydrophobic	_	_	JJ	_	_	_	_	_
24	molecules	_	_	NNS	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	or	_	_	CC	_	_	_	_	_
27	those	_	_	DT	_	_	_	_	_
28	which	_	_	WDT	_	_	_	_	_
29	display	_	_	VBP	_	_	_	_	_
30	a	_	_	DT	_	_	_	_	_
31	strong	_	_	JJ	_	_	_	_	_
32	chemical	_	_	JJ	_	_	_	_	_
33	affinity	_	_	NN	_	_	_	_	_
34	for	_	_	IN	_	_	_	_	_
35	the	_	_	DT	_	_	_	_	_
36	matrix	_	_	NN	_	_	_	_	_
37	components	_	_	NNS	_	_	_	_	_
38	,	_	_	,	_	_	_	_	_
39	are	_	_	VBP	_	_	_	_	_
40	released	_	_	VBN	_	_	_	_	_
41	more	_	_	RBR	_	_	_	_	_
42	gradually	_	_	RB	_	_	_	_	_
43	(	_	_	-LRB-	_	_	_	_	_
44	e.	_	_	FW	_	_	_	_	_
45	g.	_	_	FW	_	_	_	_	_
46	,	_	_	,	_	_	_	_	_
47	streptomycin	_	_	NN	_	_	_	_	_
48	,	_	_	,	_	_	_	_	_
49	sulfamethoxazole-trimethoprim	_	_	NN	_	_	_	_	_
50	,	_	_	,	_	_	_	_	_
51	cefazolin	_	_	NN	_	_	_	_	_
52	,	_	_	,	_	_	_	_	_
53	enocitabine	_	_	FW	_	_	_	_	_
54	etc.	_	_	FW	_	_	_	_	_
55	)	_	_	-RRB-	_	_	_	_	_
56	.	_	_	.	_	_	_	_	_


1	Thus	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	some	_	_	DT	_	_	_	_	_
4	compounds	_	_	NNS	_	_	_	_	_
5	need	_	_	VBP	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	be	_	_	VB	_	_	_	_	_
8	modified	_	_	VBN	_	_	_	_	_
9	chemically	_	_	RB	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	become	_	_	VB	_	_	_	_	_
12	more	_	_	RBR	_	_	_	_	_
13	hydrophobic	_	_	JJ	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	resulting	_	_	VBG	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	a	_	_	DT	_	_	_	_	_
18	prolonged	_	_	VBN	_	_	_	_	_
19	retention	_	_	NN	_	_	_	_	_
20	within	_	_	IN	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	matrix	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Conversely	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	proteolytic	_	_	JJ	_	_	_	_	_
5	degradation	_	_	NN	_	_	_	_	_
6	may	_	_	MD	_	_	_	_	_
7	be	_	_	VB	_	_	_	_	_
8	required	_	_	VBN	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	speed	_	_	VB	_	_	_	_	_
11	up	_	_	RP	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	diffusion	_	_	NN	_	_	_	_	_
14	process	_	_	NN	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	Lastly	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	fibrin	_	_	NN	_	_	_	_	_
4	matrix	_	_	NN	_	_	_	_	_
5	proteolysis	_	_	NN	_	_	_	_	_
6	through	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	action	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	thrombin	_	_	NN	_	_	_	_	_
11	or	_	_	CC	_	_	_	_	_
12	plasmin	_	_	NN	_	_	_	_	_
13	induces	_	_	VBZ	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	release	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	entrapped	_	_	VBN	_	_	_	_	_
18	compounds	_	_	NNS	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	order	_	_	NN	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	restrict	_	_	VB	_	_	_	_	_
5	this	_	_	DT	_	_	_	_	_
6	breakdown	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	matrix	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	co-entrapment	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	proteolysis	_	_	NN	_	_	_	_	_
15	inhibitors	_	_	NNS	_	_	_	_	_
16	(	_	_	-LRB-	_	_	_	_	_
17	aprotinin	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	matrix	_	_	NN	_	_	_	_	_
20	metalloproteinases	_	_	NNS	_	_	_	_	_
21	inhibitors	_	_	NNS	_	_	_	_	_
22	such	_	_	JJ	_	_	_	_	_
23	as	_	_	IN	_	_	_	_	_
24	galardin	_	_	NN	_	_	_	_	_
25	)	_	_	-RRB-	_	_	_	_	_
26	was	_	_	VBD	_	_	_	_	_
27	investigated	_	_	VBN	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_
29	Ahmed	_	_	NNP	_	_	_	_	_
30	et	_	_	FW	_	_	_	_	_
31	al.	_	_	FW	_	_	_	_	_
32	identified	_	_	VBN	_	_	_	_	_
33	in	_	_	IN	_	_	_	_	_
34	their	_	_	PRP$	_	_	_	_	_
35	model	_	_	NN	_	_	_	_	_
36	(	_	_	-LRB-	_	_	_	_	_
37	i.	_	_	FW	_	_	_	_	_
38	e.	_	_	FW	_	_	_	_	_
39	,	_	_	,	_	_	_	_	_
40	chondroprogenitor	_	_	NN	_	_	_	_	_
41	clonal	_	_	JJ	_	_	_	_	_
42	cell	_	_	NN	_	_	_	_	_
43	line	_	_	NN	_	_	_	_	_
44	)	_	_	-RRB-	_	_	_	_	_
45	the	_	_	DT	_	_	_	_	_
46	enzymes	_	_	NNS	_	_	_	_	_
47	responsible	_	_	JJ	_	_	_	_	_
48	for	_	_	IN	_	_	_	_	_
49	fibrin	_	_	NN	_	_	_	_	_
50	gel	_	_	NN	_	_	_	_	_
51	breakdown	_	_	NN	_	_	_	_	_
52	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	appeared	_	_	VBD	_	_	_	_	_
3	that	_	_	IN	_	_	_	_	_
4	metalloproteinases	_	_	NNS	_	_	_	_	_
5	(	_	_	-LRB-	_	_	_	_	_
6	MMP-2	_	_	NNP	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	MMP-3	_	_	NNP	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	MMP-9	_	_	NNP	_	_	_	_	_
11	)	_	_	-RRB-	_	_	_	_	_
12	were	_	_	VBD	_	_	_	_	_
13	secreted	_	_	VBN	_	_	_	_	_
14	concomitantly	_	_	RB	_	_	_	_	_
15	with	_	_	IN	_	_	_	_	_
16	fibrin	_	_	NN	_	_	_	_	_
17	hydrogels	_	_	NNS	_	_	_	_	_
18	breakdown	_	_	NN	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	They	_	_	PRP	_	_	_	_	_
2	also	_	_	RB	_	_	_	_	_
3	noted	_	_	VBD	_	_	_	_	_
4	high	_	_	JJ	_	_	_	_	_
5	plasmin	_	_	NN	_	_	_	_	_
6	activity	_	_	NN	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	conditioned	_	_	VBN	_	_	_	_	_
10	media	_	_	NNS	_	_	_	_	_
11	during	_	_	IN	_	_	_	_	_
12	hydrogel	_	_	NN	_	_	_	_	_
13	breakdown	_	_	NN	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	Then	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	they	_	_	PRP	_	_	_	_	_
4	demonstrated	_	_	VBD	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	aprotinin	_	_	NN	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	galardin	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	combination	_	_	NN	_	_	_	_	_
12	or	_	_	CC	_	_	_	_	_
13	separately	_	_	RB	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	prevented	_	_	VBD	_	_	_	_	_
16	fibrin	_	_	NN	_	_	_	_	_
17	hydrogels	_	_	NNS	_	_	_	_	_
18	degradation	_	_	NN	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	Figure	_	_	NN	_	_	_	_	_
2	4	_	_	CD	_	_	_	_	_


1	summarizes	_	_	VBZ	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	modifications	_	_	NNS	_	_	_	_	_
4	which	_	_	WDT	_	_	_	_	_
5	can	_	_	MD	_	_	_	_	_
6	be	_	_	VB	_	_	_	_	_
7	made	_	_	VBN	_	_	_	_	_
8	on	_	_	IN	_	_	_	_	_
9	fibrin	_	_	NN	_	_	_	_	_
10	matrix	_	_	NN	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	regulate	_	_	VB	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	release	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	entrapped	_	_	VBN	_	_	_	_	_
17	agents	_	_	NNS	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	5.2	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Modifying	_	_	VBG	_	_	_	_	_
2	Fibrin	_	_	NN	_	_	_	_	_
3	and/or	_	_	NN	_	_	_	_	_
4	Active	_	_	JJ	_	_	_	_	_
5	Agents	_	_	NNS	_	_	_	_	_
6	for	_	_	IN	_	_	_	_	_
7	Efficient	_	_	JJ	_	_	_	_	_
8	Combination	_	_	NN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	Delivery	_	_	NN	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	some	_	_	DT	_	_	_	_	_
3	instances	_	_	NNS	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	fibrin	_	_	NN	_	_	_	_	_
6	exhibits	_	_	VBZ	_	_	_	_	_
7	innate	_	_	JJ	_	_	_	_	_
8	affinity	_	_	NN	_	_	_	_	_
9	for	_	_	IN	_	_	_	_	_
10	therapeutics	_	_	NNS	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	growth	_	_	NN	_	_	_	_	_
13	factors	_	_	NNS	_	_	_	_	_
14	but	_	_	CC	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	other	_	_	JJ	_	_	_	_	_
17	cases	_	_	NNS	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	covalent	_	_	JJ	_	_	_	_	_
21	attachment	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	these	_	_	DT	_	_	_	_	_
24	compounds	_	_	NNS	_	_	_	_	_
25	to	_	_	TO	_	_	_	_	_
26	fibrin	_	_	NN	_	_	_	_	_
27	is	_	_	VBZ	_	_	_	_	_
28	considered	_	_	VBN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	generally	_	_	RB	_	_	_	_	_
3	requires	_	_	VBZ	_	_	_	_	_
4	chemical	_	_	JJ	_	_	_	_	_
5	modifications	_	_	NNS	_	_	_	_	_
6	with	_	_	IN	_	_	_	_	_
7	reactive	_	_	JJ	_	_	_	_	_
8	functional	_	_	JJ	_	_	_	_	_
9	groups	_	_	NNS	_	_	_	_	_
10	(	_	_	-LRB-	_	_	_	_	_
11	thiols	_	_	NNS	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	azides	_	_	NNS	_	_	_	_	_
14	)	_	_	-RRB-	_	_	_	_	_
15	allowing	_	_	VBG	_	_	_	_	_
16	a	_	_	DT	_	_	_	_	_
17	stable	_	_	JJ	_	_	_	_	_
18	association	_	_	NN	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	Then	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	reduction/hydrolysis	_	_	NN	_	_	_	_	_
4	reactions	_	_	NNS	_	_	_	_	_
5	or	_	_	CC	_	_	_	_	_
6	enzymatic	_	_	JJ	_	_	_	_	_
7	cleavage	_	_	NN	_	_	_	_	_
8	mediate	_	_	VBP	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	release	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	active	_	_	JJ	_	_	_	_	_
13	molecules	_	_	NNS	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	was	_	_	VBD	_	_	_	_	_
3	shown	_	_	VBN	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	this	_	_	DT	_	_	_	_	_
6	approach	_	_	NN	_	_	_	_	_
7	prolongs	_	_	VBZ	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	delivery	_	_	NN	_	_	_	_	_
10	phase	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	growth	_	_	NN	_	_	_	_	_
13	factors	_	_	NNS	_	_	_	_	_
14	for	_	_	IN	_	_	_	_	_
15	example	_	_	NN	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	As	_	_	IN	_	_	_	_	_
2	another	_	_	DT	_	_	_	_	_
3	illustration	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	covalently	_	_	JJ	_	_	_	_	_
6	binding	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	BMP	_	_	NN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	RGD	_	_	NN	_	_	_	_	_
11	sequences	_	_	NNS	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	fibrin	_	_	NN	_	_	_	_	_
14	allows	_	_	VBZ	_	_	_	_	_
15	interactions	_	_	NNS	_	_	_	_	_
16	with	_	_	IN	_	_	_	_	_
17	bone	_	_	NN	_	_	_	_	_
18	marrow	_	_	NN	_	_	_	_	_
19	stromal	_	_	NN	_	_	_	_	_
20	cells	_	_	NNS	_	_	_	_	_
21	through	_	_	IN	_	_	_	_	_
22	integrin	_	_	NN	_	_	_	_	_
23	surface	_	_	NN	_	_	_	_	_
24	receptors	_	_	NNS	_	_	_	_	_
25	that	_	_	WDT	_	_	_	_	_
26	triggered	_	_	VBD	_	_	_	_	_
27	downstream	_	_	JJ	_	_	_	_	_
28	signaling	_	_	NN	_	_	_	_	_
29	pathways	_	_	NNS	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	More	_	_	RBR	_	_	_	_	_
2	sophisticated	_	_	JJ	_	_	_	_	_
3	constructions	_	_	NNS	_	_	_	_	_
4	have	_	_	VBP	_	_	_	_	_
5	been	_	_	VBN	_	_	_	_	_
6	tested	_	_	VBN	_	_	_	_	_
7	.	_	_	.	_	_	_	_	_


1	Starting	_	_	VBG	_	_	_	_	_
2	from	_	_	IN	_	_	_	_	_
3	BMP-2	_	_	NNP	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	Schmoekel	_	_	NNP	_	_	_	_	_
6	et	_	_	FW	_	_	_	_	_
7	al.	_	_	FW	_	_	_	_	_
8	propose	_	_	VB	_	_	_	_	_
9	a	_	_	DT	_	_	_	_	_
10	tripartite	_	_	JJ	_	_	_	_	_
11	fusion	_	_	NN	_	_	_	_	_
12	protein	_	_	NN	_	_	_	_	_
13	denoted	_	_	VBN	_	_	_	_	_
14	as	_	_	IN	_	_	_	_	_
15	TG-pl-BMP-2	_	_	NNP	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	Under	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	control	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	blood	_	_	NN	_	_	_	_	_
7	transglutaminase	_	_	NN	_	_	_	_	_
8	factor	_	_	NN	_	_	_	_	_
9	XIIIa	_	_	NNP	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	N-terminal	_	_	JJ	_	_	_	_	_
13	transglutaminase	_	_	NN	_	_	_	_	_
14	substrate	_	_	NN	_	_	_	_	_
15	domain	_	_	NN	_	_	_	_	_
16	(	_	_	-LRB-	_	_	_	_	_
17	TG	_	_	NN	_	_	_	_	_
18	)	_	_	-RRB-	_	_	_	_	_
19	provides	_	_	VBZ	_	_	_	_	_
20	a	_	_	DT	_	_	_	_	_
21	covalent	_	_	JJ	_	_	_	_	_
22	attachment	_	_	NN	_	_	_	_	_
23	to	_	_	TO	_	_	_	_	_
24	fibrin	_	_	NN	_	_	_	_	_
25	during	_	_	IN	_	_	_	_	_
26	coagulation	_	_	NN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	upon	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	action	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	cell-activated	_	_	JJ	_	_	_	_	_
9	plasmin	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	central	_	_	JJ	_	_	_	_	_
13	plasmin	_	_	NN	_	_	_	_	_
14	substrate	_	_	NN	_	_	_	_	_
15	domain	_	_	NN	_	_	_	_	_
16	(	_	_	-LRB-	_	_	_	_	_
17	pl	_	_	NNP	_	_	_	_	_
18	)	_	_	-RRB-	_	_	_	_	_
19	gives	_	_	VBZ	_	_	_	_	_
20	a	_	_	DT	_	_	_	_	_
21	cleavage	_	_	NN	_	_	_	_	_
22	site	_	_	NN	_	_	_	_	_
23	for	_	_	IN	_	_	_	_	_
24	the	_	_	DT	_	_	_	_	_
25	local	_	_	JJ	_	_	_	_	_
26	release	_	_	NN	_	_	_	_	_
27	of	_	_	IN	_	_	_	_	_
28	the	_	_	DT	_	_	_	_	_
29	attached	_	_	VBN	_	_	_	_	_
30	growth	_	_	NN	_	_	_	_	_
31	factor	_	_	NN	_	_	_	_	_
32	from	_	_	IN	_	_	_	_	_
33	the	_	_	DT	_	_	_	_	_
34	fibrin	_	_	NN	_	_	_	_	_
35	matrix	_	_	NN	_	_	_	_	_
36	.	_	_	.	_	_	_	_	_


1	Lastly	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	C-terminal	_	_	JJ	_	_	_	_	_
5	human	_	_	JJ	_	_	_	_	_
6	BMP-2	_	_	NNP	_	_	_	_	_
7	domain	_	_	NN	_	_	_	_	_
8	displays	_	_	VBZ	_	_	_	_	_
9	an	_	_	DT	_	_	_	_	_
10	osteogenic	_	_	JJ	_	_	_	_	_
11	activity	_	_	NN	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	As	_	_	IN	_	_	_	_	_
2	an	_	_	DT	_	_	_	_	_
3	alternative	_	_	NN	_	_	_	_	_
4	to	_	_	TO	_	_	_	_	_
5	active	_	_	JJ	_	_	_	_	_
6	molecules	_	_	NNS	_	_	_	_	_
7	derivatization	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	fibrin	_	_	NN	_	_	_	_	_
10	functionalization	_	_	NN	_	_	_	_	_
11	can	_	_	MD	_	_	_	_	_
12	also	_	_	RB	_	_	_	_	_
13	be	_	_	VB	_	_	_	_	_
14	achieved	_	_	VBN	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	For	_	_	IN	_	_	_	_	_
2	example	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	to	_	_	TO	_	_	_	_	_
5	facilitate	_	_	VB	_	_	_	_	_
6	BMP	_	_	NN	_	_	_	_	_
7	interaction	_	_	NN	_	_	_	_	_
8	with	_	_	IN	_	_	_	_	_
9	a	_	_	DT	_	_	_	_	_
10	fibrin	_	_	NN	_	_	_	_	_
11	matrix	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	Yang	_	_	NNP	_	_	_	_	_
14	et	_	_	FW	_	_	_	_	_
15	al.	_	_	FW	_	_	_	_	_


1	grafted	_	_	VBN	_	_	_	_	_
2	heparin	_	_	NN	_	_	_	_	_
3	onto	_	_	IN	_	_	_	_	_
4	fibrin	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	this	_	_	DT	_	_	_	_	_
7	leading	_	_	VBG	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	electrostatic	_	_	JJ	_	_	_	_	_
10	interactions	_	_	NNS	_	_	_	_	_
11	between	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	negative	_	_	JJ	_	_	_	_	_
14	charges	_	_	NNS	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	heparin	_	_	NN	_	_	_	_	_
17	sulfate	_	_	NN	_	_	_	_	_
18	groups	_	_	NNS	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	positive	_	_	JJ	_	_	_	_	_
23	charges	_	_	NNS	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	BMPs	_	_	NNS	_	_	_	_	_
26	amino	_	_	JJ	_	_	_	_	_
27	acid	_	_	NN	_	_	_	_	_
28	residues	_	_	NNS	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	Interestingly	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	heparin	_	_	NN	_	_	_	_	_
4	presence	_	_	NN	_	_	_	_	_
5	slowed	_	_	VBD	_	_	_	_	_
6	down	_	_	RP	_	_	_	_	_
7	fibrin	_	_	NN	_	_	_	_	_
8	degradation	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	consequently	_	_	RB	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	release	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	loaded	_	_	VBN	_	_	_	_	_
16	BMPs	_	_	NNPS	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	Similar	_	_	JJ	_	_	_	_	_
2	observations	_	_	NNS	_	_	_	_	_
3	were	_	_	VBD	_	_	_	_	_
4	made	_	_	VBN	_	_	_	_	_
5	with	_	_	IN	_	_	_	_	_
6	FGF	_	_	NNP	_	_	_	_	_
7	.	_	_	.	_	_	_	_	_


1	Despite	_	_	IN	_	_	_	_	_
2	positive	_	_	JJ	_	_	_	_	_
3	effects	_	_	NNS	_	_	_	_	_
4	reported	_	_	VBN	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	literature	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	there	_	_	EX	_	_	_	_	_
9	are	_	_	VBP	_	_	_	_	_
10	several	_	_	JJ	_	_	_	_	_
11	drawbacks	_	_	NNS	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	fibrin	_	_	NN	_	_	_	_	_
14	or	_	_	CC	_	_	_	_	_
15	growth	_	_	NN	_	_	_	_	_
16	factors/proteins	_	_	NNS	_	_	_	_	_
17	functionalization	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	First	_	_	JJ	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	all	_	_	DT	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	it	_	_	PRP	_	_	_	_	_
6	requires	_	_	VBZ	_	_	_	_	_
7	specific	_	_	JJ	_	_	_	_	_
8	skills	_	_	NNS	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	it	_	_	PRP	_	_	_	_	_
12	is	_	_	VBZ	_	_	_	_	_
13	time	_	_	NN	_	_	_	_	_
14	consuming	_	_	VBG	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	expensive	_	_	JJ	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	Furthermore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	proteins	_	_	NNS	_	_	_	_	_
4	functionality	_	_	NN	_	_	_	_	_
5	can	_	_	MD	_	_	_	_	_
6	be	_	_	VB	_	_	_	_	_
7	altered	_	_	VBN	_	_	_	_	_
8	by	_	_	IN	_	_	_	_	_
9	these	_	_	DT	_	_	_	_	_
10	modifications	_	_	NNS	_	_	_	_	_
11	.	_	_	.	_	_	_	_	_


1	Indeed	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	covalent	_	_	JJ	_	_	_	_	_
4	binding	_	_	NN	_	_	_	_	_
5	can	_	_	MD	_	_	_	_	_
6	mask	_	_	VB	_	_	_	_	_
7	active	_	_	JJ	_	_	_	_	_
8	sites	_	_	NNS	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	thus	_	_	RB	_	_	_	_	_
11	affecting	_	_	VBG	_	_	_	_	_
12	their	_	_	PRP$	_	_	_	_	_
13	bioactivity	_	_	NN	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	As	_	_	IN	_	_	_	_	_
2	an	_	_	DT	_	_	_	_	_
3	alternative	_	_	JJ	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	non-modified	_	_	JJ	_	_	_	_	_
6	compounds	_	_	NNS	_	_	_	_	_
7	can	_	_	MD	_	_	_	_	_
8	be	_	_	VB	_	_	_	_	_
9	internalized	_	_	VBN	_	_	_	_	_
10	into	_	_	IN	_	_	_	_	_
11	particles	_	_	NNS	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	slow	_	_	VB	_	_	_	_	_
15	down	_	_	RP	_	_	_	_	_
16	their	_	_	PRP$	_	_	_	_	_
17	release	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_
19	Wang	_	_	NNP	_	_	_	_	_
20	et	_	_	FW	_	_	_	_	_
21	al.	_	_	FW	_	_	_	_	_
22	developed	_	_	VBD	_	_	_	_	_
23	a	_	_	DT	_	_	_	_	_
24	sophisticated	_	_	JJ	_	_	_	_	_
25	system	_	_	NN	_	_	_	_	_
26	which	_	_	WDT	_	_	_	_	_
27	could	_	_	MD	_	_	_	_	_
28	serve	_	_	VB	_	_	_	_	_
29	to	_	_	TO	_	_	_	_	_
30	deliver	_	_	VB	_	_	_	_	_
31	low-molecular	_	_	JJ	_	_	_	_	_
32	weight	_	_	NN	_	_	_	_	_
33	hydrophilic	_	_	JJ	_	_	_	_	_
34	drugs	_	_	NNS	_	_	_	_	_
35	.	_	_	.	_	_	_	_	_


1	They	_	_	PRP	_	_	_	_	_
2	used	_	_	VBD	_	_	_	_	_
3	an	_	_	DT	_	_	_	_	_
4	antithrombosis	_	_	JJ	_	_	_	_	_
5	drug	_	_	NN	_	_	_	_	_
6	(	_	_	-LRB-	_	_	_	_	_
7	i.	_	_	FW	_	_	_	_	_
8	e.	_	_	FW	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	Tirofiban®	_	_	NNP	_	_	_	_	_
11	)	_	_	-RRB-	_	_	_	_	_
12	as	_	_	IN	_	_	_	_	_
13	a	_	_	DT	_	_	_	_	_
14	drug	_	_	NN	_	_	_	_	_
15	model	_	_	NN	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	Drug-loaded	_	_	JJ	_	_	_	_	_
2	liposomes	_	_	NNS	_	_	_	_	_
3	were	_	_	VBD	_	_	_	_	_
4	first	_	_	RB	_	_	_	_	_
5	encapsulated	_	_	VBN	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	fibrin	_	_	NN	_	_	_	_	_
9	gel	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	then	_	_	RB	_	_	_	_	_
13	combined	_	_	VBN	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	chitosan	_	_	NN	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	To	_	_	TO	_	_	_	_	_
2	document/characterize	_	_	VB	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	vitro	_	_	NN	_	_	_	_	_
6	drug	_	_	NN	_	_	_	_	_
7	release	_	_	NN	_	_	_	_	_
8	profile	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	different	_	_	JJ	_	_	_	_	_
11	parameters	_	_	NNS	_	_	_	_	_
12	were	_	_	VBD	_	_	_	_	_
13	studied	_	_	VBN	_	_	_	_	_
14	including	_	_	VBG	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	surface	_	_	NN	_	_	_	_	_
17	charge	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	liposomes	_	_	NNS	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	pore	_	_	NN	_	_	_	_	_
23	size	_	_	NN	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	chitosan	_	_	NN	_	_	_	_	_
26	structure	_	_	NN	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	and	_	_	CC	_	_	_	_	_
29	the	_	_	DT	_	_	_	_	_
30	crosslinking	_	_	VBG	_	_	_	_	_
31	degree	_	_	NN	_	_	_	_	_
32	of	_	_	IN	_	_	_	_	_
33	fibrin	_	_	NN	_	_	_	_	_
34	gels	_	_	NNS	_	_	_	_	_
35	.	_	_	.	_	_	_	_	_


1	All	_	_	PDT	_	_	_	_	_
2	these	_	_	DT	_	_	_	_	_
3	experimental	_	_	JJ	_	_	_	_	_
4	conditions	_	_	NNS	_	_	_	_	_
5	offered	_	_	VBD	_	_	_	_	_
6	different	_	_	JJ	_	_	_	_	_
7	prolonged	_	_	JJ	_	_	_	_	_
8	releases	_	_	NNS	_	_	_	_	_
9	without	_	_	IN	_	_	_	_	_
10	altering	_	_	VBG	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	composite	_	_	JJ	_	_	_	_	_
13	bioactivity	_	_	NN	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	All	_	_	PDT	_	_	_	_	_
2	these	_	_	DT	_	_	_	_	_
3	modifications	_	_	NNS	_	_	_	_	_
4	are	_	_	VBP	_	_	_	_	_
5	summarized	_	_	VBN	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_


1	Figure	_	_	NN	_	_	_	_	_
2	4	_	_	CD	_	_	_	_	_


1	.	_	_	.	_	_	_	_	_

